These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17845986)

  • 1. [Gemcitabine and pemetrexed: novel associations and mechanisms of resistance].
    Sablin MP; Le Tourneau C; El Maalouf G; Raymond E; Faivre S
    Bull Cancer; 2007; 94 Spec No Actualites():S149-54. PubMed ID: 17845986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pemetrexed/gemcitabine combination in pancreatic cancer.
    Kindler HL
    Cancer; 2002 Aug; 95(4 Suppl):928-32. PubMed ID: 12209673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
    Adjei AA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):30-4. PubMed ID: 12571808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro].
    Zhu ZX; Zhang WM; Jia G; Zhou J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):149-52. PubMed ID: 20118008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
    Ngeow J; Toh CK
    Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
    Adjei AA
    Lung Cancer; 2001 Dec; 34 Suppl 4():S103-5. PubMed ID: 11742712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
    Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
    Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
    Le Chevalier T
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed in pancreatic cancer.
    Kindler HL
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):49-53. PubMed ID: 12571811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
    Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
    Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.
    De Pas TM; Toffalorio F; Catania C; Noberasco C; Spitaleri G; Spaggiari L; De Braud F
    Ann Oncol; 2009 Oct; 20(10):1747-8. PubMed ID: 19690055
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gemcitabine and pemetrexed update].
    Spano JP; Bay JO
    Bull Cancer; 2007; 94 Spec No Actualites():S83. PubMed ID: 17845975
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of pemetrexed in non-small cell lung cancer.
    Longo-Sorbello GS; Chen B; Budak-Alpdogan T; Bertino JR
    Cancer Invest; 2007 Feb; 25(1):59-66. PubMed ID: 17364559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
    Cameron RB; Hou D
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):496-504. PubMed ID: 23174177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V; Patel JD; Argiris A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.